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Over the past two years, the photopheresis treatment program at Yale-New Haven Hospital
has treated 32 patients with cutaneous T-cell lymphoma. There were 19 erythrodermic patients
who had photopheresis as their first systemic therapy. Five of these cleared 75 percent of their
skin and the majority of erythrodermics achieved an improved quality of life. Those with best
responses were treated earlier in the course of their disease and had more normal proportions of
CD4 and CD8 subsets when compared to patients with poor responses. In addition, patients with
tumor stage disease and those patients in relapse after intensive radio- and chemotherapy were
treated with photopheresis. These results demonstrate that photopheresis has a role in the
management ofcutaneous T-cell lymphoma.
Extracorporeal photochemotherapy (photopheresis) was initially reported in 1987 to
produce clinical improvement in a majority of patients with erythrodermic cutaneous
T-cell lymphoma [1]. That report consisted of a multi-center clinical trial, with
patients being treated for a minimum of one year. Roughly one-fourth of erythroder-
mic patients went into remission, and one-fourth did not improve significantly. The
remaining patients achieved a marked improvement in skin condition and quality of
life but still had demonstrable CTCL.
At the time ofthe clinical trial, patients were treated with the UVAR I instrument,
which had a treatment time ofsix to seven hours. Since the completion ofthe trial, the
UVAR II system, with its treatment time ofthree to four hours, has been used. In this
report, we present the results ofusing the UVAR II system in patients with cutaneous
T-cell lymphoma (CTCL).
The results of this treatment in the management of erythrodermic patients are
discussed in comparison to the initial clinical trial. In addition, patients with tumor
state disease have had photopheresis incorporated into their treatment regimens with
promising results.
PATIENT POPULATION
During the first two years of operation, the photopheresis program at Yale-New
Haven Hospital entered a total of32 CTCL patients on to treatment for a minimum of
six months each. The patients ranged in age from 39 to 77. There were three distinct
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TABLE 1
Stratification of Patients Treated with Photopheresis at Yale-New Haven
Hospital
Three categories ofCTCL patients
1. Erythroderma
19 with extracorporeal photochemotherapy as first systemic 14
3 after chemotherapy
2. Tumor Stage Disease
2 without radiation 14
2 with spot therapy of tumors
2 cleared by 3,600 rads E beam
3 in relapse after beam/chemotherapy
3. Widespread Disease After Beam/Chemotherapy
3 in relapse > I year
clinical groups: erythroderma, tumor stage, and those with widespread disease in
relapse for more than one year after multi-modality therapy. As shown in Table 1, the
patients represent a variety of stages of CTCL. The majority of patients were those
with erythroderma receiving photopheresis as their first line of therapy. Skin involve-
ment by the disease was assessed by examining each patient when they presented for
treatment. Skin involvement ofa particular region was graded on a 0 to 4 scale as done
in conjunction with the initial clinical trial [1]. Surface involvement is thus graded
according to the percentage ofsurface involved anddegree (0 to 4) to which that area is
involved. Responses are graded into three categories: patients clearing either 75
percent of their surface involvement, patients involving more than 25 percent of their
involvement but less than 75 percent, and those with less than 25 percent involve-
ment.
LABORATORY STUDIES
The diagnosis of CTCL was made histologically in all cases. The determination of
peripheral blood lymphocyte surface markers utilized flow cytometry with antibodies
to CD3, CD4, and BE-2 [2]. The method for measuring 8-methoxypsoralen (8-MOP)
levels was that of Gasparro et al. [3], and these measurements were performed in the
Yale Photobiology Laboratory.
PHOTOPHERESIS
Photopheresis therapy was performed by having patients ingest .6 mg/kg
8-methoxypsoralen. A 16-gauge catheter was placed in an antecubital vein and blood
separated on a discontinuous centrifuge with collection ofbuffy coat cells. After 240 cc
ofbuffy coat had been collected, the leukocyte-rich fraction was then diluted with 200
cc saline and 200 cc plasma. The buffy coat is then irradiated by ultraviolet A light
(UVA)-emitting bulbs. The irradiation commenced with the initial collection of buffy
coat; the latter feature constitutes the major difference between the UVAR I and
UVAR 11 instruments. The former machine did not start irradiation until all buffy
coat collection was complete, so that the total treatment time was decreased with the
second-generation unit.
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DISEASE DURATION
RESPONDERS NONRESPONDERS
4-
3-
FIG. 1. A comparison of
2 the five best responders to
the five least responders
1 shows that best responses
occurred when therapy was
initiated earlier in the course
of the disease. The time
intervals are the time from
disease onset to commence-
lyr 1-2yr >2yr lyr 1-2yr >2yr ment ofphotopheresis.
TREATMENT REGIMENS
Patients were initially treated for two consecutive days at every-four-week intervals.
Treatments were conducted at the bedside during a three-day hospitalization; this
regimen was maintained for six months. After six months, a clinical evaluation was
performed. Those demonstrating marked clinical improvement were maintained on the
four-weekly treatment schedule. Their treatments would be continued until maximum
clearing appeared. An additional six months of therapy after this point was adminis-
tered to insure the stability ofthe response. Once stable for this additional six months,
patients are then gradually tapered by adding one week per cycle every three cycles.
After this schedule has been extended to one cycle of therapy every eight weeks for
three times, their therapy is stopped.
Adjunctive therapy was considered for patients with responses that were incomplete.
Methotrexate adjunctive therapy consisted of an initial dose of 15 mg between
treatment cycles. If this dosage was well tolerated, the dose was advanced to weekly,
with no dosing within seven days before or after a cycle ofphotopheresis. Azathioprine
adjunct was initiated at 100 mg/day. Nitrogen mustard was utilized at 10 mg percent
concentration in Aquaphor. Total body electron beam therapy was administered as
described in previous studies from this institution [4]. A total dose of 3,600 rads was
given in 36 sessions.
RESULTS
Erythroderma
Twenty-two patients with erythroderma were treated. Nineteen of these had
photopheresis as the first line oftherapy. The beneficial response appeared on the head
and upper trunk first, with a decrease in erythroderma and scaling. As the erythro-
derma improved in a cephalocaudal manner, patients had less chills and edema.
Pruritis and palmo-plantar involvement tended to be the last areas to resolve. Five ofHEALD ET AL.
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the patients cleared over 75 percent oftheir skin involvement. Ten patients cleared 25
to 75 percent, while four patients had less than 25 percent improvement.
Features ofResponders and Non-Responders
The five patients with greatest therapeutic response were compared to the five with
the smallest response. Two features characterized the responding group (see Figs. 1
and 2). Patients in the most responsive group had mean CD4, CD8, and 4/8 ratios of
55.4, 15.6, and 5.27, respectively. In comparison, the CD4, CD8, and 4/8 ratios of the
least responsive group were 74.8, 7.8, and 39.6. Another feature which characterized
the responsive group was the shorter interval between onset ofdisease and the start of
photopheresis (see Fig. 1).
Adjunctive Therapy
For those patients in the intermediate response group, adjunctive therapy has the
potential of working with photopheresis to lead to a greater improvement of the
disease. Patients considered for adjunctive therapy had erythroderma with a stable but
not acceptable improvement in response to photopheresis. Repeat skin biopsies were
performed to demonstrate disease and to ensure that the patient had not developed
tumor or plaque stage, which would dictate a change in therapy overall.
In eight patients, the test dose of 15 mg methotrexate between two cycles of
photopheresis (two weeks after one cycle and before the other), was well tolerated. All
eight patients were advanced to the schedule of three doses between treatments. Of
these patients, two had previously begun oral daily prednisone (40 mg/day) to improve
flares of their disease. Prednisone was begun at 40 mg per day for two weeks, then
decreased to 30 mg per day for one week, and 20 mg per day for one week. After a
four-week course, attempts were then made to taper to 5 mg per week. Any return of
disease activity returned the prednisone dose to 20 mg, and attempts to taper were
re-started after addition of adjunctive therapy. When the prednisone could not be
successfully tapered, the methotrexate was initiated. Cessation of prednisone was
achieved within two months ofmethotrexate, and in both patients an improved clinical
status appeared and stabilized. The total time on prednisone was five months and three
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and a halfmonths for these two patients. In the other six patients, methotrexate led to a
complete remission in one, greater than 50 percent clearing in two, and a stabilized
pattern in three. The adjunctive use of steroids in photopheresis is best utilized for
symptomatic short-term management. All patients had been weaned to an oral
prednisone dose of 20 mg every other day or less prior to starting photopheresis.
Topical steroids were initiated with .05 percent hydrocortisone in Aquaphor. If
pruritus did not improve and the patient had received a minimum of six cycles of
photopheresis, there would be a trial of 0.1 percent triamcinolone applied at night. If
this treatment were unsuccessful, a one-month trial of nightly halcinonide (Halog)
applications would be attempted. One patient required two months ofhalcinonide, but
otherwise these agents were used sparingly.
Azathioprine therapy was initiated in three patients. In one, it was instituted to
facilitate the tapering of that patient's prednisone dose but was unsuccessful; thus the
azathioprine was discontinued after two months. One patient who commenced
photopheresis with a white blood cell count ofover 50,000 cells/mm3 had azathioprine
initiated at the start to help lower this elevated white blood cell count. Over 18 months,
his azathioprine dose was 100 mg per day, and the patient gradually improved. After
the white blood cell count decreased to <12,000, the azathioprine was discontinued,
and the patient has maintained a white blood cell count in that range for the past two
years. The third patient had azathioprine therapy initiated to try to improve his
intermediate response. After one year, there was no marked improvement, and therapy
was discontinued. One patient who had an intermediate response was evaluated for
adjunctive therapy and found to have superficial involvement with lymphoma and with
a scant dermal infiltrate (Fig. 3A-3C). Adjunctive topical nitrogen mustard ointment
therapy was initiated and, after four months, there was clinical improvement in
conjunction with histologic improvement (Fig. 3C) in a biopsy from the same site.
Prior to initiation of photopheresis, six of the patients had attempted standard
psoralen/ultraviolet A (PUVA) photochemotherapy without success. There were four
patients who had PUVA therapy attempted after they had achieved an intermediate
response stage. Three were unable to tolerate .5 joules/cm2 due to an accentuation of
erythroderma and malaise. One patient was able to tolerate therapy and has continued
on a once-weekly regimen for the past year.
Taper ofTherapy
For those patients with a successful response to therapy, photopheresis treatments
were gradually tapered as outlined. In all patients, there was a mild flare of disease
activity at some point in the weaning process. This reaction necessitated a return to the
four-weekly regimen before once again attempting a taper. One patient has discontin-
ued completely, one is at six-weekly treatments, and four are at five-week treatment
intervals.
Tumor Stage Disease
The preliminary results of treating tumor stage with photopheresis alone showed
that tumors did not resolve within a few monthsoftherapy. One patient has a remission
ofover two years' duration from when total body radiotherapy and photopheresis were
begun. A second patient is in theseventh month ofremission. Patients treated with spot
radiotherapy on photopheresis have had two recurrences each. These were subse-
quently treated with additional spot therapy.HEALD ET AL.sj,,. _....wr-+e:'"'XSt
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FIG. 3. A skin biopsy showing disease before initiation of photopheresis (A), after 12 months of therapy
(B), and after the initiation of nitrogen mustard therapy (C).
8-MOP Levels
The availability of liquid 8-methoxypsoralen in a capsule (OXSORALEN
ULTRA®) led to discontinuance of the crystalline preparation. The liquid preparation
is more reliably and rapidly absorbed. Therapy was changed to begin with a dose of0.5
mg/kg oxsoralen Ultra, and blood collection was initiated 60-90 minutes after
ingestion. Once the buffy coat collections were completed and the final stage of
irradiation had begun, a sample was removed and analyzed for 8-MOP concentration.
As can be shown in Fig. 4, there is tremendous variation over a range ofmg/kg dosages
for 8-MOP. The target "bag level" is to be >50 ng/ml. This goal was reliably achieved
in doses >0.5 mg/kg oxsoralen Ultra. If the 8-MOP were extremely elevated (>200
ng/ml) or if the patients were experiencing nausea, the dose was lowered and, on the
next treatment, an 8-MOP bag level would be checked.
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BAG LEVELS OF 8-MOP
LIQUID PSORALEN
8-MOP (NG/ML)
350
300
250
200
150 _
100 _
50 _
l_ l_l_l_l_l_l_ l_ FIG. 4. 8-MOP levels in the treatment
0.5 0.55 0.6 0.65 0.7 0.75 0.8 0.85 0.9 0.95 1 bag as a function of dose administered
MG/KG 8-MOP orally.
Septic Complications
Over the two years ofoperation, there have been approximately 1,400 photopheresis
treatments performed at Yale-New Haven Hospital; these include the CTCL patients
and those undergoing clinical trials still in progress. To date, there have been no
episodes of bacterial sepsis associated with photopheresis. One patient experienced
disseminated herpes simplex infection three days after photopheresis. The patient had
been pretreated with electron beam followed by six months ofchemotherapy. Despite
that, he still had erythroderma and tumors at the time of initiation of photopheresis.
On his second and third cycles, herpetic infection recurred again at three days after
starting photopheresis. The therapy was then discontinued.
DISCUSSION
The initial study ofphotopheresis for erythrodermic CTCL demonstrated the ability
of this treatment to improve the quality of life for the majority of those treated. The
study entry criteria for that report included a white blood count <15,000/mm3 [1].
The patients in this report were those with more varied stages ofCTCL. Erythroderma
patients comprised the majority of the photopheresis treatment population at Yale-
New Haven Hospital. The results oftherapy in this group are similar to that previously
reported in the multi-center trial. Five of 19 patients cleared over 75 percent of their
skin involvement, similar to the seven of 29 erythrodermic patients in the original
study. In addition, three patients had a minimal response while receiving photopheresis
as a first-line therapy. An additional two patients achieved unacceptable responses
despite an initial improvement with photopheresis. Taken together, these five patients
comprise one-fourth of the Yale-New Haven erythroderma treatment group. Again,
this result is similar to the five of 29 erythrodermic patients who did not respond to
photopheresis in the earlier report. One difference is that, at 12 months, two of the
partial responders had achieved >25 percent clearing, but this condition was not
maintained so that, in this report, they would be considered non-responders.
Adjunctive therapy has not been previously reported with photopheresis. In the
multi-center trial, patients were limited to 1.0 percent hydrocortisone. With patients in
the intermediate response group, there was a need to use adjunctive therapy to yield
further improvement. The ideal adjunct would be one which is relatively non-toxic and
non-immunosuppressive in order to work with the immunostimulating events ofHEALD ET AL.
photopheresis. Low-dose oral methotrexate meets these criteria. In the eight patients
who initiated this therapy, five had demonstrable improvement, while three patients
stabilized. Even the maximal dose of 15 mg three times a month is so low that concern
about liver toxicity does not warrant a liver biopsy so long as patients abstain from
alcohol. The synergy of methotrexate with this setting could be multifactorial.
Psoralen-thymidine adducts require new thymidine bases in order to be repaired.
Interference with repair of photoadducts may represent one mechanism. Another is
that cell cycle changes induced by the methotrexate may hold more of the more rapidly
growing malignant cells at a more PUVA-susceptible point in the cell cycle. And,
finally, given the success of methotrexate in psoriasis, this agent may have an effect
against the psoriasiform tissue reaction in general. By itself, low-dose methotrexate has
not been reliably effective in treating Sezary syndrome [5,6]. Indeed, many patients in
the initial clinical trial and in this report had undergone trials with it before initiating
photopheresis.
One of the three patients who were started on azathioprine had a demonstrable
improvement with a reduction in white blood count while on azathioprine-photophere-
sis. This agent is preferentially toxic to T cells and more immunosuppressive than
methotrexate. Its use in transplantation is well established. Given the smaller
experience with this agent and the more reliable results with the less immunosuppres-
sive methotrexate, it appears azathioprine should be considered as a second-line
adjunct.
In one patient, the decision to use topical mustard as an adjunct was made based on
the predominance of epidermotropic disease with scant dermal disease. With the
improvement noted, it appears these two therapies can be successfully combined.
Given the reactions of erythrodermic patients to PUVA and electron beams, it is
questionable that either of these two could be combined in any therapeutic program
involving Sezary syndrome patients. The discomfort exhibited by our patients initiat-
ing these adjuncts argues against their use in this setting.
The comparison of the five best responding patients to the five least responding
patients reveals several interesting guidelines in the selection of patients. As shown in
Fig. 1, the fact that the best responders had begun on therapy earlier in the course of
their illness suggests that this treatment should indeed be considered the first line of
therapy for erythrodermic CTCL. Patients appear to do better when therapy is started
earlier in the course of the disease. In addition, those erythroderma patients heavily
pre-treated did not respond as well, which may also reflect the fact that they were
treated later in the course of their disease. The other finding which appears to correlate
with a good response is the presence of suppressor cells in sufficient number. As seen in
Fig. 2, the best responders had a smaller CD4 compartment and larger CD8
compartment when compared to non-responders. The latter finding suggests that the
CD8 subset may be important for a response to therapy. Whether this subset is
stimulated by treatment on the target of therapy is an interesting dilemma. The
experimental work by Perez et al. in this issue suggests that suppressor cells are
activated by the infusion of photoinactivated lymphocytes.
A gradual taper of photopheresis was found to be the best way to discontinue
therapy. In the weaning process, the early recurrence of disease often appeared in the
week prior to therapy. This fact suggests that the stimulating effects of photopheresis
wear off and that the timing of intervals is important to generating and maintaining a
therapeutic response. Based on these results, it is best to wait until the clinical picture
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has stabilized for six months after maximum improvement. At that point, intervals are
increased by one week per cycle every three treatment cycles.
Adequate 8-MOP levels in the irradiated compartment are important for the
photoinactivation of lymphocytes. In the first clinical trial, therapeutic doses of
8-MOP were assessed on the basis ofa blood level drawn two hours after an oral doseof
crystalline psoralen. The results from our patients suggest that the best way to assess
8-MOP dosage is done on the leukapheresis sample after it has been diluted with saline
to facilitate the irradiation process. The target level is >50 ng/ml. This level could be
reliably achieved with doses in the range of .5 mg/kg. Also, in light of the "first-pass
effect" described by Gasparro et al. in this issue, it is best not to assess 8-MOP
absorption the first time a patient has been exposed to the drug. When therapy is
initiated, an 8-MOP "treatment bag" level should be checked, provided that the
patient has previously ingested psoralen (which many have in the course ofattempting
PUVA).
In the first published report of photopheresis therapy for CTCL, toxicity was
minimal and there was little evidence of immunosuppression. In the group of patients
with CTCL reported here, toxicity again appears minimal. Opportunistic infections
with atypical mycobacteria and fungi have not appeared. Despite the propensity of
erythrodermic patients to develop septic complications due to the loss of cutaneous
barrier function, this condition was not a problem. In fact, the prevention of these
phenomena by marked cutaneous improvementcould probably bedemonstrated with a
larger number ofpatients.
The tumor stage/erythroderma patient whoexperienced three bouts ofdisseminated
herpes after three consecutive cycles of therapy exhibited the most disturbing
complication of therapy. Thus, in patients with advanced disease (recurrent tumor
stage and erythroderma following radiation and chemotherapy), there may be concern
for exacerbating viral disease.
Studies of survival in CTCL have identified several features which worsen the
prognosis. The development oferythroderma is associated with a reduction in survival,
as is the presence of tumors [7,8]. Given the improvement in erythrodermic patients
with photopheresis, it is anticipated that survival statistics will also improve, as this
cohort of patients is watched over a long follow-up period. It is also possible that the
prolongation of remission in tumor stage patients may also result in prolonged survival
in this group as a result of photopheresis.
Photopheresis should not be utilized as a single agent in tumor stage disease. Two
patients did not have demonstrable reductions in tumor burden as a result of therapy.
Radiotherapy is a useful treatment for ablating tumors. Unfortunately there is a limit
as to the total amount of radiotherapy that can be delivered to the skin. Thus, a
desirable goal in this stage of the disease is to prolong radiotherapy remissions. The
two-year remission in one patient who presented with over 20 tumors is encouraging.
From this patient, it is apparent that photopheresis can safely be used as a follow-up to
electron beam therapy. The two patients who underwent spot radiotherapy both
experienced recurrences elsewhere on their skin. By comparing these results with that
of total body radiotherapy, it appears the latter is better for preventing recurrences.
Presumably, the total body dosing eradicates microscopic metastases of the disease
which are not clinically apparent at the time of spot radiotherapy. The eventual
comparison ofspot to total body radiotherapy by way ofsurvival statistics will require
more patients followed for longer periods oftime to be statistically validated.638 HEALD ET AL.
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PLAQUE - PATCH TUMOR ERYTHRODERM
/ \RADmm ~ RX4 FIG. 5. A treatment algorithm for
PUVA4* NM2 A
RAD RX 4WBC CTCL shows the role of photopheresis
+1- RETINOID I -, _/ LP in the management of many stages of RETINOID LHE O the disease. The solid arrows are the CHEMO- , currently accepted modalities of thera-
ECP py. The hollow arrows are those cur-
rently under study. ECP, photo-
pheresis; NM2, nitrogen mustard; LP,
PROTOCOL THERAPIES: a-INTERFERON, ANTI-CD3 leukapheresis; BMT, bone marrow
DEOXYCOFORMYCIN, ALLO/AUTO BMT transplant.
SUMMARY
The results oftreating erythrodermic CTCL patients with photopheresis are similar
to those previously reported. The erythroderma patients did better when therapy was
instituted earlier in the course of the disease before the patients were heavily
pre-treated. The safety of the procedure has also been demonstrated. Adjunctive
therapy has been shown to be synergistic with photopheresis. Thus, this novel
photomedical therapy has safely moved from its clinical trial, where its solo effects
were noted, to its role as a component of therapy (Fig. 5) of a variety of patients with
CTCL.
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